MS
Michael Shetzline
Senior Vice President, Chief Medical Officer and Head of Research and Development
Ironwood PharmaceuticalsTherapeutic Areas
Ironwood Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LINZESS (linaclotide) | Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) | Approved |
| Apraglutide | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Phase 3 |